Cargando…
Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
Mantle cell lymphoma (MCL) is an aggressive and largely incurable subtype of non‐Hodgkin's lymphoma. Venetoclax has demonstrated efficacy in MCL patients with relapsed or refractory disease, however response is variable and less durable than CLL. This may be the result of co‐expression of other...
Autores principales: | Zhao, Xiaoxian, Bodo, Juraj, Chen, Ruoying, Durkin, Lisa, Souers, Andrew J., Phillips, Darren C., Hsi, Eric D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176003/ https://www.ncbi.nlm.nih.gov/pubmed/35847704 http://dx.doi.org/10.1002/jha2.48 |
Ejemplares similares
-
Aggressive, early resistant and relapsed mantle cell lymphoma distinct extrinsic microenvironment highlighted by transcriptome analysis
por: Le Bris, Yannick, et al.
Publicado: (2022) -
Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R‐CHOP
por: Procházka, Vít, et al.
Publicado: (2020) -
Lymphoplasmacytic lymphoma and marginal zone lymphoma involving bone marrow: A diagnostic dilemma. Useful clinicopathological features to accurate the diagnosis
por: García‐Abellás, Patricia, et al.
Publicado: (2022) -
Phase Ib study of avadomide (CC‐122) in combination with rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma and follicular lymphoma
por: Nastoupil, Loretta J., et al.
Publicado: (2022) -
Primary central nervous system lymphoma: Inter‐compartmental progression
por: Raval, Vishal, et al.
Publicado: (2022)